Tempus AI, Inc. (TEM) Earnings Call Transcripts
Tempus AI, Inc.'s Latest Earnings Call - Q1 FY2026
Tempus AI reported strong financial results for Q1 2026, with revenue reaching $348.1 million, a 36% increase year-over-year. The company's diagnostic revenue was $261.1 million, driven by oncology business growth. Data and applications revenue was $87 million, up 40.5% YoY. Tempus raised its full-year guidance to a range of $1.5 billion to $1.6 billion, with adjusted EBITDA expected at $65 million. This guidance increase, along with robust growth in both diagnostics and data businesses, could positively impact the stock.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $348.1M (beat) |
| Diagnostic Revenue | $261.1M (beat) |
| Data and Applications Revenue | $87M (beat) |
| Adjusted EBITDA | $65M (guidance) (beat) |
| MRD Growth | 500% (neutral) |
Guidance from management
Tempus raised its full-year revenue guidance to $1.5 billion to $1.6 billion, with adjusted EBITDA expected at $65 million, reflecting strong business performance.
What management said
I'll handle the adjusted EBITDA piece, and then Eric can address MRD. Much like the prior year, the progression should build as the months pass. In Q1 we saw roughly $13+ million of year-over-year improvement. Q2 should look much the same. Clearly, the second half carries more weight for data, and that drives wider margins and a greater amount falling through to the bottom line. As we noted early in the year, we're l...
Dan, the sole point I'd tack on is this: nothing is being suggested about volumes just because we've got that reimbursement upside. Clearly, with reimbursement gains, nailing down precisely when they'll land is tough. As you know, our volume patterns remain really robust. Those two lines in the deck aren't hinting at anything.
What analysts pressed on
Analysts expressed concerns about the timing of FDA submissions and the impact of reimbursement on MRD growth. Questions also focused on the sustainability of data business growth and the visibility into achieving revenue targets.
Main topics on the call
- Revenue Growth — Revenue for Q1 2026 was $348.1 million, up 36% year-over-year. Diagnostic revenue grew by 35%, with oncology unit growth at 28%. Data and applications revenue increased by 40.5%, driven by data licensing and modeling bus...
- Guidance Increase — Tempus increased its full-year revenue guidance to $1.5 billion to $1.6 billion, with adjusted EBITDA expected at $65 million. This reflects strong performance across main business segments.
- Pharma Collaborations — Tempus expanded its pharma collaborations, adding Merck and expanding with Gilead. These strategic partnerships are expected to enhance data business growth.
- FDA Submissions — No significant updates on FDA submissions for XF. An amendment for tumor-only cases is expected imminently, which could accelerate migration to ADLT version.
Read the full Tempus AI, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Tempus AI, Inc.
Tempus AI, Inc. (TEM) is a publicly listed company in the Life Sciences Tools and Services industry, within the Health Care sector. It trades on NASDAQ and is based in US. EarningsCalls.dev maintains a full-text archive of its earnings call transcripts — 9 calls on record spanning August 6, 2024 to July 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics. The latest calls are free to read; the full history is available through our REST API.
Earnings Call History
EarningsCalls.dev has 9 Tempus AI, Inc. earnings call transcripts on record, spanning August 6, 2024 to July 30, 2026. Based on this history, Tempus AI, Inc. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the transcript.
- Ticker
- TEM
- Exchange
- NASDAQ
- Country
- US
- Sector
- Health Care
- Industry
- Life Sciences Tools and Services
- Calls on record
- 9
- First call
- August 6, 2024
- Most recent
- July 30, 2026
- Reporting cadence
- quarterly
| Quarter | Date | |
|---|---|---|
| Q2 FY2026 | Jul 30, 2026 | Read transcript → |
| Q1 FY2026 | May 5, 2026 | Read transcript → |
| Q4 FY2025 | Feb 24, 2026 | Read transcript → |
| Q3 FY2025 | Nov 4, 2025 | Read transcript → |
| Q2 FY2025 | Aug 8, 2025 | Read transcript → |
| Q1 FY2025 | May 6, 2025 | Read transcript → |
| Q4 FY2024 | Feb 24, 2025 | Read transcript → |
| Q3 FY2024 | Nov 4, 2024 | Read transcript → |
| Q2 FY2024 | Aug 6, 2024 | Read transcript → |